Sort   by:  
 Page size 
ProteomicsIntra-patient clonal diversity in HLA class I peptide ligand presentation
Tumor heterogeneity results from clonal diversity and evolutionary selection, and is a major cause of therapeutic resistance. Immunotherapy may exploit alternative vulnerabilities of drug resistant cells, and tumor-specific HLA peptide ligands on the cell surface are promising leads to invoke such t...
ORGANISM(S): Homo sapiens (Human) 
2020-10-26 | PXD016582 | Pride
Hla class i peptide ligands  colorectal cancer  tumor heterogeneity  patient-derived organoids  mass spectrometry  affinity proteomics 
ProteomicsIdentification of novel HLA class I-restricted hepatitis B virus peptides and their modulation by peptide editor TAPBPR
Hepatitis B virus (HBV) is the leading cause of hepatocellular carcinoma and infections remain a substantial global health problem for which no curative therapy exists. As cytotoxic CD8+ T lymphocytes are the principal effectors of natural HBV resolution, there is considerable interest in discoverin...
ORGANISM(S): Homo sapiens (Human) 
2026-07-15 | PXD078020 | Pride
Immunopeptidomics Hla Tapbpr Mhc 
Proteomicsthe landscape of phosphorylated HLA-I ligands
The identification and prediction of HLA-I–peptide interactions play an important role in our understanding of antigen recognition in infected or malignant cells. In cancer, non-self HLA-I ligands can arise from many different alterations, including non-synonymous mutations, gene fusion, cancer-spec...
ORGANISM(S): Homo sapiens (Human) 
2019-12-18 | PXD013831 | Pride
Immunopeptidomics Hla binding peptides Phosphorylations 
ProteomicsThe HLA ligandome comprises a limited repertoire of O-GlcNAcylated antigens preferentially associated with HLA-B07:02
Mass-spectrometry based immunopeptidomics has provided unprecedented insights into antigen presentation, not only charting an enormous ligandome of self-antigens, but also cancer neo-antigens and peptide antigens harbouring post-translational modifications. Here we concentrate on the latter, focusin...
ORGANISM(S): Homo sapiens (Human) 
2021-12-03 | PXD028874 | Pride
O-glcnacylation Hla-b07 Mhc Hla class i Immunopeptidomics 
ProteomicsCharacterization of the HLA class I Ligandome from Extracellular vesicles
Extracellular vesicles have shown promise in the field of anti-tumor vaccines. EVs are antigen-presenting entities capable of eliciting potent T-cell responses and have therefore being explored as cell-free based peptide vaccine vectors. However, whether the EV ligandome sufficiently resembles the c...
ORGANISM(S): Homo sapiens (Human) 
2021-07-05 | PXD021177 | Pride
Ev vaccines Extracellular vesicles Immunopeptidomics Ligandome Hla-i 
ProteomicsMHC class I loaded ligands from breast cancer cell lines: A potential HLA-I-typed antigen collection
We sought to build a catalog of epitopes presented by breast cancers using a renewable resource of well-characterized breast cancer cell lines. Starting from 70 breast cancer cell lines, we measured MHC class I abundance and used pre-existing RNAseq data to identify either HLA-A*02 or MHC class I-po...
ORGANISM(S): Homo sapiens (Human) 
2018-01-16 | PXD006406 | Pride
Immune system Mass spectrometry Human Mhc class 1 ligands Hla typing Peptide sequencing Breast cancer Cell lines Immunoprecipitation Rna-seq 
ProteomicsNatural and cryptic peptides dominate the immunopeptidome of atypical teratoid rhabdoid tumors.
Atypical teratoid/rhabdoid tumors (AT/RT) are highly aggressive CNS-tumors of infancy and early childhood. Hallmark is the surprisingly simple genomics with a truncating mutation in the SMARCB1 gene as the oncogenic driver. Nevertheless, AT/RTs are infiltrated by immune cells and even clonally expan...
ORGANISM(S): Homo sapiens (Human) 
2022-05-31 | PXD033935 | Pride
Human Primary at/rt tumors Hla-i and hla-ii 
ProteomicsHLA-I peptidomics od Meningioma tissues - Peptide length distribution and multiple specificity in naturally presented HLA-I ligands
HLA-I molecules bind short peptides and present them to CD8+ T cells for TCR recognition. The length of HLA-I ligands typically ranges from 8 to 12 amino acids, but high variability is observed between different alleles. Here we used recent HLA peptidomics data to analyze in an unbiased way peptide ...
ORGANISM(S): Homo sapiens (Human) 
2019-07-31 | PXD009925 | Pride
Hla binding motifs Hla class i peptides Meningioma 
ProteomicsZapnometinib treatment and influenza A virus infection induce alteration on the HLA class I ligandome of human lung adenocarcinoma cells
Targeting cellular factors is considered a promising approach to combat viral infection and overcome the resistance issue associated with direct-acting antiviral (DAA) drugs administration. In the context of drug repurposing strategies, we have previously explored the antiviral efficacy of the MEK i...
ORGANISM(S): Homo sapiens (Human) 
2026-06-15 | PXD041578 | Pride
Influenza a virus Ligandome analysis Mek inhibitors Zapnometinib Mhc-i Lc-ms/ms 
ProteomicsB27 inmunopeptidome in vaccinica infected cells
Identification of natural human leukocyte antigen (HLA) ligandome is a key element to understand the cellular immune responses. Advanced high throughput mass spectrometry analyses identify a relevant, but not complete, fraction of the many tens of thousands of self-peptides generated by the antigen ...
ORGANISM(S): Homo sapiens (Human) 
2021-12-22 | PXD027859 | Pride
Hla-b*27 Vaccinica Hla Immunopeptidomics 
Sort   by:  
 Page size